Mouse monoclonal antibody raised against synthetic phosphopeptide of TP53.
Synthetic phosphopeptide (conjugated with KLH) corresponding to residues surrounding S46 of human TP53.
Quality Control Testing:
Phospho-p53 Ser46 Antibody detects phosphorylated p53 at serine 46 in an immunoprecipitates using anti-p53 specific polyclonal antibody, by western blotting or phosphorylated recombinant p53 only when phosphorylated at serine 46 in vitro, by western blotting.
Western Blot (1-2 ug/mL) ELISA (1 ug/mL) The optimal working dilution should be determined by the end user.
In 10 mM HEPES/KOH, 150 mM NaCl, pH 7.5 (50% glycerol)
Store at -20°C. Aliquot to avoid repeated freezing and thawing.
H2O2 and Adriamycin treatment induce phosphorylation of p53 at serine 46 in MCF-7 cells which expresses wild type p53. Detected by Immunoprecipitation-western blotting using anti-p53 polyclonal antibody and p53 (phospho S46) monoclonal antibody, clone TK-4D4 (Cat # MAB0011).
Western Blot (Recombinant protein)
ELISA for measuring of recombinant CK2 alpha/beta and CK2 alpha'/beta activities using p53 (phospho S46) monoclonal antibody, clone TK-4D4 (Cat # MAB0011).
This gene encodes tumor protein p53, which responds to diverse cellular stresses to regulate target genes that induce cell cycle arrest, apoptosis, senescence, DNA repair, or changes in metabolism. p53 protein is expressed at low level in normal cells and at a high level in a variety of transformed cell lines, where it's believed to contribute to transformation and malignancy. p53 is a DNA-binding protein containing transcription activation, DNA-binding, and oligomerization domains. It is postulated to bind to a p53-binding site and activate expression of downstream genes that inhibit growth and/or invasion, and thus function as a tumor suppressor. Mutants of p53 that frequently occur in a number of different human cancers fail to bind the consensus DNA binding site, and hence cause the loss of tumor suppressor activity. Alterations of this gene occur not only as somatic mutations in human malignancies, but also as germline mutations in some cancer-prone families with Li-Fraumeni syndrome. Multiple p53 variants due to alternative promoters and multiple alternative splicing have been found. These variants encode distinct isoforms, which can regulate p53 transcriptional activity. [provided by RefSeq
p53 antigen,p53 transformation suppressor,p53 tumor suppressor,phosphoprotein p53,transformation-related protein 53